Cencora Inc

Cencora Inc(COR)股票分析

$340.920

-0.477 (-0.14%)收盤時

Loading chart…
最高
343.310
開盤
343.310
成交量加權均價
341.08
成交量
1.98M
市值
44.89B
最低
339.010
成交金額
674.96M
企業價值/稅息折舊攤銷前利潤(TTM)
12.29

Cencora, Inc. is a global pharmaceutical sourcing and distribution services company. The Company helps both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The Company operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services.

AI 分析 of Cencora Inc (COR)

買進

Cencora Inc is a good buy right now due to its current price of $340.92 being below the analyst price targets, with Baird and Citi both setting targets at $370. The RSI is at 87.341, indicating strong momentum, and the company has shown a solid revenue growth trend with Q2 revenue at $78.4 billion, up 3.8% year-over-year. However, a key risk is the high debt-to-equity ratio of 361.93%, which could impact financial stability.

分析師評級(15)

上檔空間 +21.84%
持有
7 買進
8 持有
0 賣出
目前: 340.92
最低
400.00
平均
415.38
最高
440.00

RBC Capital

2026-08-19

目標價

$330

Sector Perform

Leerink

2026-08-12

目標價

—

優於大盤

Morgan Stanley

2026-08-07

目標價

$346

增持

Baird

2026-08-06

目標價

$370

優於大盤

Evercore ISI

2026-08-06

目標價

$350

優於大盤

估值指標

Cencora Inc(COR)目前預期本益比為 15.70,5 年平均預期本益比為 15.39。

預期本益比

合理
5 年均值 P/E
15.39
目前P/E
15.70
高估
17.62
低估
13.17

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
11.49
目前EV/EBITDA
12.29
高估
13.67
低估
9.31

預期股價營收比

高估
5 年均值 P/S
0.15
目前P/S
0.19
高估
0.17
低估
0.12

Alphio AI 對 COR 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%COR

$387.16

情境價格

基

基準

基準 · 50%COR

$367.49

情境價格

悲

悲觀

悲觀 · 25%COR

$348.87

情境價格

持有 COR 的大戶

T

The Woodbridge Company Limited

+ 持有COR

+13.82%

3個月報酬率

W

Walgreens Boots Alliance Holdings LLC

+ 持有COR

+12.15%

3個月報酬率

M

Mawer Investment Management Ltd.

+ 持有COR

+10.13%

3個月報酬率

D

Diversified Trust Company, Inc.

+ 持有COR

+7.08%

3個月報酬率

B

Burgundy Asset Management Ltd.

+ 持有COR

+6.08%

3個月報酬率

C

Carmignac Gestion SA

+ 持有COR

+5.97%

3個月報酬率

事件時間軸

2026-09-25 (ET)

08:30:00

Cencora Appoints Robert Sanchez as Independent Director

2026-08-12 (ET)

13:00:00

Cencora Reaffirms FY2026 EPS Guidance of $17.75 to $17.95

13:00:00

Cencora Sees FY26 Adjusted EPS of $17.75-$17.95

2026-06-15 (ET)

16:30:00

Cencora HR Executive Announces Retirement

資訊

COR 常見問題 —— 由 Alphio AI 解答

Cencora, Inc. is a global pharmaceutical sourcing and distribution services company. The Company helps both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The Company operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services. It operates in the Healthcare sector (WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRI industry).

Cencora Inc is a good buy right now due to its current price of $340.92 being below the analyst price targets, with Baird and Citi both setting targets at $370. The RSI is at 87.341, indicating strong momentum, and the company has shown a solid revenue growth trend with Q2 revenue at $78.4 billion, up 3.8% year-over-year. However, a key risk is the high debt-to-equity ratio of 361.93%, which could impact financial stability.

15 analysts cover COR: 7 rate it Buy, 8 Hold and 0 Sell. The average price target is 415.38.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易